Data & Analysis
Data & Analysis · page 4
- Industry Trends
Is the German Cannabis Boom Slowing Down, or Simply Normalising?
Germany’s cannabis imports, according to the latest figures from BfArM, nearly tripled in size in 2025, cementing it beyond any doubt as the engine behind Europe’s medical cannabis boom.
- Clinical Research
Rescheduling Will Reprice Medical IP, Not Retail Footprints
US cannabis rescheduling is unlikely to trigger a land grab.
- Retail & Brands
Canada’s Cannabis Retail Market Reaches C$5.5bn in 2024/25, But Growth Slowing
Canadian adult-use cannabis sales reached C$5.5 billion in the fiscal year ending 31 March 2025, a 6.1% increase on the prior year, according to new data from Statistics Canada, though the pace of growth continued to slow for the third consecutive year.
- Clinical Research
The Cannabis Mental Health Evidence Gap: Association vs. Causation
In our latest Beyond the Abstract, we dive into cannabis use and its impact on mental health, a controversial and understudied field, but one of vital importance for both patient safety and potential relief for millions.
- Industry Trends
Organigram Acquires Sanity Group: When Big Tobacco Moves into Cannabis
By Dr Sebastian Marincolo, Director of Strategic Content & Editorial, Weed.de Canadian cannabis company Organigram Global has agreed to acquire Berlin’s Sanity Group for up to 227 million euros, financed in large part by a roughly 65 million Canadian dollar capital injection from its largest shareholder, British American Tobacco (BAT).
- Industry Trends
Germany’s Post-CanG Import Surge Loses Steam as Q4 Growth Stalls
Germany’s imports for 2025 surpassed 200 tonnes for the first time, exceeding the country’s already revised import quota for the second time in a year.
- Clinical Research
‘You Can’t Treat What You Can’t Measure’ – The Plan to Make the Endocannabinoid System Impossible to Ignore
Across global cannabis markets, the average levels of THC content are continuing a sustained, exponential and well-documented rise.
- CBD Market
Clinical Evidence vs. Food Law: Europe’s CBD Dilemma
The CBD sector has had a turbulent few weeks on both sides of the Channel, with the European Food Safety Authority (EFSA) terminating four novel food applications, just days after announcing incredibly restrictive new safety limits.
- Industry Trends
US Cannabis Rescheduling: A Victory or a Federal Trap?
US cannabis rescheduling, much like President Donald Trump who is rightly credited for finally pushing it forward, has sucked all the oxygen out of the room for the last two years.
- Industry Trends
New Report: Poland Medical Cannabis Market Data Shows Full Post-Ban recovery, With a Catch
Polish pharmacies dispensed nearly 5,450 kilograms of dried cannabis flower in 2025, a 12% increase from the prior year, according to new data obtained by Prohibition Partners.
- Industry Trends
Insurance Has Become a Critical Benchmark for Cannabis Industry Maturity
Since the emergence of the legal cannabis industry across the Western world, operators have persistently been forced to deal with an issue faced by few counterparts in established sectors: they can’t get insured.
- International Regulation
Relm and Prohibition Partners Launch Cannabis Risk Briefing for Emerging and High-Growth Industries
Relm Insurance (Relm), the leading insurer focused on emerging industries, today released its Risk Briefing: Cannabis 2026, an inaugural global report produced in collaboration with Prohibition Partners, the industry-first discovery platform for B2B cannabis.
